Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Gastrointestinal 2Thoracic 1Sarcoma 1Genitourinary 1CNS 1

Conditions

Colorectal Neoplasms 38Stomach Neoplasms 24Rectal Neoplasms 19Pancreatic Neoplasms 17Lymphoma, Large B-Cell, Diffuse 14Colonic Neoplasms 14Esophageal Neoplasms 12Adenocarcinoma Of Esophagus 12Carcinoma, Non-Small-Cell Lung 10Neoplasms 9Neoplasm Metastasis 9Adenocarcinoma 9Cholangiocarcinoma 8Biliary Tract Neoplasms 6Ovarian Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Hepatocellular 4Lymphoma, Non-Hodgkin 3Lymphoma 3Lung Neoplasms 3Gallbladder Neoplasms 3Endometrial Neoplasms 3Carcinoma 3Bile Duct Neoplasms 3Advanced Solid Tumors 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Spinocerebellar Degenerations 2Recurrence 2

Interventions

pembrolizumab 26Paclitaxel 25Carboplatin 19Bevacizumab 13Specimen Handling 11Magnetic Resonance Spectroscopy 9Doxorubicin 8Cisplatin 8Taxes 7Biopsy 7olaparib 6lenvatinib 6Fulvestrant 6durvalumab 5dostarlimab 5Nivolumab 5Megestrol Acetate 5Letrozole 5Gemcitabine 5Docetaxel 5trastuzumab deruxtecan 4Trastuzumab 4Tirzepatide 4Progestins 4Medroxyprogesterone Acetate 4Fluorouracil 4palbociclib 3ipatasertib 3atezolizumab 3abemaciclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Oxaliplatin × 90 days × Clear all
NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05919264 2026-05-28

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Parabilis Medicines, Inc.

Phase 1/2 Recruiting
595 enrolled
CNSGastrointestinalGenitourinaryGynecologicSarcoma

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡